Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

dc.contributor.authorMcGowan, M. P.en_ZA
dc.contributor.authorTardif, J. C.en_ZA
dc.contributor.authorCeska, R.en_ZA
dc.contributor.authorBurgess, L. J.en_ZA
dc.contributor.authorSoran, H.en_ZA
dc.contributor.authorGouni-Berthold, I.en_ZA
dc.contributor.authorWagener, G.en_ZA
dc.contributor.authorChasan-Taber, S.en_ZA
dc.date.accessioned2013-02-23T09:31:11Z
dc.date.available2013-02-23T09:31:11Z
dc.date.issued2012-11-13
dc.descriptionThe original publication available at www.plos.orgen_ZA
dc.descriptionCITATION: McGowan, M. P. et al. 2012. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE, 7(11):e49006, doi:10.1371/journal.pone.0049006.
dc.description.abstractObjectives: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated. Methods and Results: Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n = 58) were $18 years with LDL-C $7.8 mmol/L or LDL-C $5.1 mmol/L plus CHD disease, on maximally tolerated lipid-lowering therapy that excluded apheresis. Weekly subcutaneous injections of mipomersen 200 mg (n = 39) or placebo (n = 19) were added to lipid-lowering therapy for 26 weeks. Main outcome: percent reduction in LDL-C from baseline to 2 weeks after the last dose of treatment. Mipomersen (n = 27) reduced LDL-C by 36%, from a baseline of 7.2 mmol/L, for a mean absolute reduction of 2.6 mmol/L. Conversely, mean LDL-C increased 13% in placebo (n = 18) from a baseline of 6.5 mmol/L (mipomersen vs placebo p,0.001). Mipomersen produced statistically significant (p,0.001) reductions in apolipoprotein B and lipoprotein(a), with no change in high-density lipoprotein cholesterol. Mild-to-moderate injection site reactions were the most frequently reported adverse events with mipomersen. Mild-to-moderate flu-like symptoms were reported more often with mipomersen. Alanine transaminase increase, aspartate transaminase increase, and hepatic steatosis occurred in 21%, 13% and 13% of mipomersen treated patients, respectively. Adverse events by category for the placebo and mipomersen groups respectively were: total adverse events, 16(84.2%), 39(100%); serious adverse events, 0(0%), 6(15.4%); discontinuations due to adverse events, 1(5.3%), 8(20.5%) and cardiac adverse events, 1(5.3%), 5(12.8%). Conclusion: Mipomersen significantly reduced LDL-C, apolipoprotein B, total cholesterol and non-HDL-cholesterol, and lipoprotein(a). Mounting evidence suggests it may be a potential pharmacologic option for lowering LDL-C in patients with severe hypercholesterolemia not adequately controlled using existing therapies. Future studies will explore alternative dosing schedules aimed at minimizing side effects.en_ZA
dc.description.urihttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049006
dc.description.versionPublisher's versionen_ZA
dc.format.extent10 pages
dc.identifier.citationMcGowan, M. P. et al. 2012. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE, 7(11):e49006, doi:10.1371/journal.pone.0049006.en_ZA
dc.identifier.issn1932-6203 (online)
dc.identifier.other10.1371/journal.pone.0049006
dc.identifier.urihttp://hdl.handle.net/10019.1/79601
dc.language.isoen_ZAen_ZA
dc.publisherPLoSen_ZA
dc.rights.holderAuthors retain copyright
dc.subjectOligonucleotideen_ZA
dc.subjectApolipoprotein Ben_ZA
dc.subjectLow density lipoproteinsen_ZA
dc.subjectatherogenic lipoproteinsen_ZA
dc.subjectHypercholesterolemiaen_ZA
dc.subjectAntilipemic agentsen_ZA
dc.subjectMipomersenen_ZA
dc.titleRandomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapyen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
McGowan.pdf
Size:
415.79 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description: